Investing in Endava PLC Sponsored ADR (DAVA)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)87.87245
Intrinsic value (DCF)29.1815
Graham-Dodd Method15.40-40
Graham Formula42.7368

Company description

DAVA Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs for various disease areas. Based in Chicago, Illinois, the company was founded in 2014 with the goal of creating novel therapeutics to benefit patients with unmet medical needs. The company's research and development efforts are centered on leveraging the power of computer-aided drug design to discover and develop innovative drug candidates targeting a range of diseases, including cancer, inflammation, and autoimmune disorders. DAVA's proprietary platform combines state-of-the-art computational techniques with medicinal chemistry expertise to identify potential drug candidates with high therapeutic potential. DAVA's pipeline includes several promising drug candidates in various stages of development, including investigational drugs for the treatment of solid tumors, autoimmune disorders, and gastrointestinal diseases. The company has also successfully entered into partnerships and collaborations with leading pharmaceutical companies to accelerate the development and commercialization of its drug candidates. In addition to its focus on drug development, DAVA also has a strong commitment to corporate responsibility and ethical business practices. The company's leadership team has a combined experience of over 50 years in the pharmaceutical industry, and they are dedicated to maintaining a culture of transparency, integrity, and respect for all stakeholders. With a mission to improve patient lives through the development of innovative therapeutics, DAVA Pharmaceuticals, Inc. is a fast-growing, dynamic company poised for continued success in the highly competitive biopharmaceutical industry.